Market ExpansionPhysicians expect the US CGM category to grow over 20%, outpacing the 17-18% forecast from market leaders, indicating strong potential for Senseonics.
Patient Base GrowthSenseonics achieved a 56% increase in its patient base in 2024, surpassing its target and demonstrating strong growth potential.
Product DifferentiationSenseonics' Eversense 365 is the only FDA-approved implantable CGM that provides continuous blood glucose monitoring for 12 months, surpassing the 10-14 days of competing platforms.